AU2002336845A1 - Globin biopolymer markers indicative of insulin resistance - Google Patents

Globin biopolymer markers indicative of insulin resistance

Info

Publication number
AU2002336845A1
AU2002336845A1 AU2002336845A AU2002336845A AU2002336845A1 AU 2002336845 A1 AU2002336845 A1 AU 2002336845A1 AU 2002336845 A AU2002336845 A AU 2002336845A AU 2002336845 A AU2002336845 A AU 2002336845A AU 2002336845 A1 AU2002336845 A1 AU 2002336845A1
Authority
AU
Australia
Prior art keywords
globin
insulin resistance
markers indicative
biopolymer markers
biopolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002336845A
Other versions
AU2002336845A8 (en
Inventor
George Jackowski
John Marshall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syn X Pharma Inc
Original Assignee
Syn X Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn X Pharma Inc filed Critical Syn X Pharma Inc
Publication of AU2002336845A8 publication Critical patent/AU2002336845A8/en
Publication of AU2002336845A1 publication Critical patent/AU2002336845A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
AU2002336845A 2001-11-23 2002-10-31 Globin biopolymer markers indicative of insulin resistance Abandoned AU2002336845A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99334301A 2001-11-23 2001-11-23
US09/993,343 2001-11-23
PCT/CA2002/001657 WO2003046556A2 (en) 2001-11-23 2002-10-31 Globin biopolymer markers indicative of insulin resistance

Publications (2)

Publication Number Publication Date
AU2002336845A8 AU2002336845A8 (en) 2003-06-10
AU2002336845A1 true AU2002336845A1 (en) 2003-06-10

Family

ID=25539418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002336845A Abandoned AU2002336845A1 (en) 2001-11-23 2002-10-31 Globin biopolymer markers indicative of insulin resistance

Country Status (3)

Country Link
JP (1) JP2005510716A (en)
AU (1) AU2002336845A1 (en)
WO (1) WO2003046556A2 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0922226T3 (en) * 1996-08-13 2003-07-07 Biovision Ag Method for recording the status of an organism by measuring peptides
JP2002537561A (en) * 1999-02-16 2002-11-05 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ Methods and apparatus for isolating and analyzing cellular protein components
CA2263063C (en) * 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
US20020160420A1 (en) * 2001-04-30 2002-10-31 George Jackowski Process for diagnosis of physiological conditions by characterization of proteomic materials
US6620787B2 (en) * 2001-04-30 2003-09-16 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2267 daltons
US20040198950A1 (en) * 2001-04-30 2004-10-07 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons
US7087435B2 (en) * 2001-04-30 2006-08-08 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons
US20040224423A1 (en) * 2001-04-30 2004-11-11 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 2056 daltons
US6620786B2 (en) * 2001-04-30 2003-09-16 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having molecular weight of 2937 daltons

Also Published As

Publication number Publication date
WO2003046556A2 (en) 2003-06-05
WO2003046556A3 (en) 2003-08-07
AU2002336845A8 (en) 2003-06-10
JP2005510716A (en) 2005-04-21

Similar Documents

Publication Publication Date Title
AU2002301310A1 (en) Polymer composition
AU2002336367A1 (en) Adamts13 genes and proteins and variants, and uses thereof
AU2002359919A1 (en) Syringe
AU2002361092A1 (en) Syringe
AU2002349673A1 (en) Insulin resistance improving agents
AU2003296369A1 (en) Imminoamines and preparation thereof
AU2002337436A1 (en) Hanger with information marker
AU2001233176A1 (en) Resistance sequences and uses thereof
AU2002345878A1 (en) Ilt3 and ilt4-related compositions and methods
AU2002335977A1 (en) Protein biopolymer markers predictive of insulin resistance
AU2002336844A1 (en) Protein biopolymer markers predictive of insulin resistance
AU2002336846A1 (en) Macroglobulin biopolymer markers indicative of insulin resistance
AU2002336847A1 (en) Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance
AU2002336845A1 (en) Globin biopolymer markers indicative of insulin resistance
AU2002336850A1 (en) Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance
AU2003271854A1 (en) Composition comprising proteinaceous material, its preparation and use
AU2002336851A1 (en) Hp biopolymer markers predictive of insulin resistance
AU2003252536A1 (en) Pesticidal fluoroalkene derivatives
AU2002361023A1 (en) Stabilizer composition, production and use thereof
AU2003299336A1 (en) Diphosphines, preparation and uses thereof
AU2002346804A1 (en) Genes coding for stress resistance and tolerance proteins
AU2002336849A1 (en) Complement c3 precursor biopolymer markers indicative of insulin resistance
AU2002350599A1 (en) Homeotic genes and proteins, and uses thereof
AU2002336848A1 (en) Apolipoprotein biopolymer markers predictive of insulin resistance
AU2002335968A1 (en) Protein biopolymer markers indicative of a disease state

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase